The addition of atezolizumab (Tecentriq) to chemotherapy demonstrated noninferior survival compared with placebo plus chemotherapy in patients with advanced or recurrent endometrial cancer, according to a presentation on the phase 3…
The addition of atezolizumab (Tecentriq) to chemotherapy demonstrated noninferior survival compared with placebo plus chemotherapy in patients with advanced or recurrent endometrial cancer, according to a presentation on the phase 3…